Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Transpl Int
; 26(8): e64-8, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23672514
ABSTRACT
Although donor-specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti-HLA antibodies were present at the time of transplantation. As a result of suspected antibody-mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti-HLA antibodies, and particularly nondonor directed antibodies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Ácidos Borônicos
/
Transplante de Rim
/
Transplante de Fígado
/
Anticorpos Monoclonais Murinos
/
Sobrevivência de Enxerto
/
Antígenos HLA
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article